The clinical values of dysregulated DNA methylation and demethylation intermediates in acute lymphoblastic leukemia

References

• Harrison, C. J. Acute lymphoblastic leukemia. Clin Lab Med. 2011; 31(4): 631-647 , ix. doi: 10.1016/j.cll.2011.08.016
   PubMed Web of Science ®Google Scholar
• Katz, A. J., Chia, V. M., Schoonen, W. M., et al. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 2015; 26(11): 1627-1642. doi: 10.1007/s10552-015-0657-6
   PubMed Web of Science ®Google Scholar
• Pui, C. H., and Evans, W. E. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354(2): 166-178. doi: 10.1056/NEJMra052603
   PubMed Web of Science ®Google Scholar
• Inaba, H., Greaves, M., and Mullighan, C. G. Acute lymphoblastic leukaemia. Lancet. 2013; 381(9881): 1943-1955. doi: 10.1016/S0140-6736(12)62187-4
   PubMed Web of Science ®Google Scholar
• Gutierrez, M. I., Siraj, A. K., Bhargava, M., et al. Concurrent methylation of multiple genes in childhood ALL: correlation with phenotype and molecular subgroup. Leukemia. 2003; 17(9): 1845-1850. doi: 10.1038/sj.leu.2403060
   PubMed Web of Science ®Google Scholar
• Milani, L., Lundmark, A., Kiialainen, A., et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood. 2010; 115(6): 1214-1225. doi: 10.1182/blood-2009-04-214668
   PubMed Web of Science ®Google Scholar
• Figueroa, M. E., Chen, S. C., Andersson, A. K., et al. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Invest. 2013; 123(7): 3099-3111. doi: 10.1172/JCI66203
   PubMed Web of Science ®Google Scholar
• Wu, X., and Zhang, Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet. 2017; 18(9): 517-534. doi: 10.1038/nrg.2017.33
   PubMed Web of Science ®Google Scholar
• Kohli, R. M., and Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013; 502(7472): 472-479. doi: 10.1038/nature12750
   PubMed Web of Science ®Google Scholar
• Moran-Crusio, K., Reavie, L., Shih, A., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011; 20(1): 11-24. doi: 10.1016/j.ccr.2011.06.001
   PubMed Web of Science ®Google Scholar
• Li, Z., Cai, X., Cai, C. L., et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011; 118(17): 4509-4518. doi: 10.1182/blood-2010-12-325241
   PubMed Web of Science ®Google Scholar
• Thabet, Y., Le Dantec, C., Ghedira, I., et al. Epigenetic dysregulation in salivary glands from patients with primary Sjogren’s syndrome may be ascribed to infiltrating B cells. J Autoimmun. 2013; 41:175-181. doi: 10.1016/j.jaut.2013.02.002
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology: acute lymphoblastic leukemia, 2. 2014
   Google Scholar
• Virely, C., Moulin, S., Cobaleda, C., et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia. 2010; 24(6): 1200-1204. doi: 10.1038/leu.2010.63
   PubMed Web of Science ®Google Scholar
• Paganin, M., and Ferrando, A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2011; 25(2): 83-90. doi: 10.1016/j.blre.2010.09.004
   PubMed Web of Science ®Google Scholar
• Mullighan, C. G., Su, X., Zhang, J., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360(5): 470-480. doi: 10.1056/NEJMoa0808253
   PubMed Web of Science ®Google Scholar
• Corn, P. G., Kuerbitz, S. J., van Noesel, M. M., et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5’ CpG island methylation. Cancer Res. 1999; 59(14): 3352-3356.
   PubMed Web of Science ®Google Scholar
• Younesian, S., Shahkarami, S., Ghaffari, P., et al. DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia. Leuk Res. 2017; 61:33–38. doi: 10.1016/j.leukres.2017.08.016
   PubMed Web of Science ®Google Scholar
• Nordlund, J., Backlin, C. L., Wahlberg, P., et al. Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol. 2013; 14(9): r105. doi: 10.1186/gb-2013-14-9-r105
   PubMed Web of Science ®Google Scholar
• Lian, C. G., Xu, Y., Ceol, C., et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012; 150(6): 1135-1146. doi: 10.1016/j.cell.2012.07.033
   PubMed Web of Science ®Google Scholar
• Yang, H., Liu, Y., Bai, F., et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 2013; 32(5): 663-669. doi: 10.1038/onc.2012.67
   PubMed Web of Science ®Google Scholar
• Ko, M., Huang, Y., Jankowska, A. M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010; 468(7325): 839-843. doi: 10.1038/nature09586
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab, O., Mullally, A., Hedvat, C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009; 114(1): 144-147. doi: 10.1182/blood-2009-03-210039
   PubMed Web of Science ®Google Scholar
• Figueroa, M. E., Abdel-Wahab, O., Lu, C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6): 553-567. doi: 10.1016/j.ccr.2010.11.015
   PubMed Web of Science ®Google Scholar
• Ntziachristos, P., Abdel-Wahab, O., and Aifantis, I. Emerging concepts of epigenetic dysregulation in hematological malignancies. Nat Immunol. 2016; 17(9): 1016-1024. doi: 10.1038/ni.3517
   PubMed Web of Science ®Google Scholar
• McKenney, A. S., and Levine, R. L. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest. 2013; 123(9): 3672-3677. doi: 10.1172/JCI67266
   PubMed Web of Science ®Google Scholar
• Scourzic, L., Mouly, E., and Bernard, O. A. TET proteins and the control of cytosine demethylation in cancer. Genome Med. 2015; 7(1): 9. doi: 10.1186/s13073-015-0134-6
   PubMed Web of Science ®Google Scholar
• Yokoi K., Yamashita K., Watanabe M. Analysis of DNA methylation status in bodily fluids for early detection of cancer. Int J Mol Sci. 2017;18:735. doi: 10.3390/ijms18040735
   Web of Science ®Google Scholar
• Nestor, C., Ruzov, A., Meehan, R., et al. Enzymatic approaches and bisulfite sequencing cannot distinguish between 5-methylcytosine and 5-hydroxymethylcytosine in DNA. Biotechniques. 2010; 48(4): 317-319. doi: 10.2144/000113403
   PubMed Web of Science ®Google Scholar
• Tang, Y., Zheng, S. J., Qi, C. B., et al. Sensitive and simultaneous determination of 5-methylcytosine and its oxidation products in genomic DNA by chemical derivatization coupled with liquid chromatography-tandem mass spectrometry analysis. Anal Chem. 2015; 87(6): 3445-3452. doi: 10.1021/ac504786r
   PubMed Web of Science ®Google Scholar
• Chowdhury, B., Cho, I. H., and Irudayaraj, J. Technical advances in global DNA methylation analysis in human cancers. J Biol Eng. 2017; 11:10. doi: 10.1186/s13036-017-0052-9
   PubMed Web of Science ®Google Scholar